For long-term investors (>2 years), today's 15% drop on reports that a patent judge might rule (as largely expected) in favor of MSN polymorph of cabozantinib while protecting the other, broader EXEL patent(s) could be good opportunity. $2B in cash and no debt on $6B market cap with $1B+ product revenues, several catalysts over the next 18 months, and a next gen Cabo in the pipeline...https://seekingalpha.com/news/3841029-exelixis-drops-quickly-on-day-four-of-cabometyx-patent-trial